Latham & Watkins Advises Amneal Pharmaceuticals in Merger with Impax Laboratories

Combination creates diversified pharmaceutical company with 5th largest generics business in the US.

October 17, 2017

Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) have announced that they have agreed to merge in an all-stock transaction. As a result of the transaction, Amneal Holdings members will own 75% and Impax shareholders will own 25% of the new company’s pro forma shares. The transaction is expected to close in the first half of 2018, subject to the satisfaction of customary closing conditions, including receipt of regulatory approvals and Impax shareholder approval.

Latham & Watkins LLP represents Amneal in the transaction with a corporate deal team led by partner Charles Ruck in New York and Orange County and partner Scott Shean in Orange County, with associates Mark Bekheit in Silicon Valley, Daniel Kecman in Washington, D.C., Lilian Balasanian in Los Angeles, Bret Stancil in Silicon Valley, Brad Guest in Washington, D.C., Emily Sairafian in Orange County, Lauren Chase in Silicon Valley, and Cassandra Wang in Silicon Valley. Advice was also provided on finance matters by partners Wesley Holmes and Jesse Sheff, with associates Sonja Pollack and Jake Burne in New York; on securities matters by counsel Ryan deFord, with associate Yi Han Goh in New York; on tax matters by partners Joseph Kronsnoble in Chicago and Nicholas DeNovio in Washington, D.C., with associate Jared Grimley in Houston; on benefits and compensation matters by partner Bradd Williamson in New York and counsel Nineveh Alkhas in Chicago, with associate Jordan Salzman in New York; on antitrust matters by partner Mandy Reeves, with associate Patrick English in Washington, D.C.; on environmental matters by partner Christopher Norton in Orange County and counsel David Langer in New York; on real estate matters by partner Hilary Shalla, with associates Meagan Licata and Kendra Perdue in Orange County; on intellectual property matters by partner Steven Chinowsky and counsel Darryl Steensma in San Diego, with associate Simon Hu in Los Angeles; on intellectual property litigation matters by partner Daniel Brown in New York; and on regulatory matters by partner Ben Haas in Washington, D.C., with associate Amy Speros in Silicon Valley.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.